download the onsite event guide - IBC Life Sciences

Event Guide 

May 12-15, 2013 • Hynes Convention Center • Boston, MA, USA 

Event Guide Sponsor: 

What's Inside... 

Agenda Overview........................................... 3 

Event Sponsors................................................ 4 

Conference Agenda 

Sunday Courses .......................................... 6-7 

Monday Sessions............................................ 8 

Tuesday Sessions................................... 10-13 

Wednesday Sessions............................ 14-16 

Exhibition Hours and Information 

Poster Presentations..................Addendum 

Meeting and Exhibit Room Map.............18 

Exhibitor List and Hall Map.......................20 

Platinum Sponsor 

Gold Sponsors 

Silver Sponsors 

Bronze Sponsors

Sunday, May 12, 2013 

Course #1: Application of Current FDA and 

10:00 am - 

ICH Guidelines to the Manufacturing and 

5:00 pm 

Analysis of Oligonucleotides (Room 202) 

Monday, May 13, 2013 

8:45 am - 

12:50 pm 

Agenda Overview with Room Assignments 

Course #2: Business and Operational 

Strategies for Successful Peptide 

Development (Room 204) 

Mipomersen: A Novel Second Generation Antisense 

Oligonucleotide for Treatment of the Rare Genetic Disorder, 

Homozygous Familial Hypercholesterolemia 

Mary P. McGowan, M.D., Senior Medical Director, Clinical Research, 

Genzyme, a Sanofi Company 

The State of Venture Capital, Startups, and Funding in 

Oligo and Peptide Therapeutics 

Bruce Booth, D.Phil., Partner, Life Sciences, Atlas Venture 

Keynote Session (Room 302/304) 

Course #3: Peptide and Oligonucleotide 

Conjugation Strategies (Room 203) 

Course #4: Physicochemical 

Characterization of Oligonucleotides 

and Peptides (Room 205) 

Poster and Exhibit Hall Hours: 3:15 pm – 6:45 pm 

Spherical Nucleic Acids (SNAs) 

Chad A. Mirkin, Ph.D., Professor, Chemistry, Northwestern University 

The Role of Drug Delivery and Device Technologies for Peptide Products 

William J. Lambert, Ph.D., Fellow, Drug Delivery and Device Development, MedImmune, Inc. 

Epitope Targeted, Protein Catalyzed Capture Agents Generated by In Situ 

Click Chemistry for Human Health Applications 

James R. Heath, Ph.D., Professor, Chemistry and Chemical Engineering, 

California Institute of Technology 

1:40 pm - 

5:30 pm Plenary Session: Updates on Commercialization of Therapeutic Candidates (Room 302/304) 

3:15 pm - 

4:30 pm Grand Opening of Poster and Exhibit Hall with Networking Refreshment Break (Exhibit Hall D) 

1:40 pm - 

5:30 pm Plenary Session (continued) (Room 302/304) 

5:30 pm - 

6:45 pm Networking, Wine and Cheese Reception in Poster and Exhibit Hall Sponsored by AIC Tedia (Exhibit Hall D) 

Tuesday, May 14, 2013 

Poster and Exhibit Hall Hours: 10:30 am – 6:15 pm 

8:00 am - 

11:15 am 

11:15 am - 

12:45 pm 

Oligonucleotide and Peptide Manufacturing, Technology 

and Product Development 

CMC Challenges and 

Solutions – Strategic Approaches 

Session Sponsored by Cepia Sanofi (Room 302) 

Strategy Discussion Forum 

Specifications for Oligonucleotide 

and Peptide Active 

Pharmaceutical Ingredients 

(Room 313) 

Emerging Technologies Showcase: 

Spotlight Presentations (Room 302) 

Sponsored by Tandem Labs and 

ST Pharm Co. Ltd. (former 

Samchully Pharm), Korea 

Oligonucleotide 

Therapeutics Discovery 

Peptide Discovery 

and Development 

Nucleic Acids Technologies 

for Molecular Diagnostics 

Room 311 Room 309 Room 310 

Single Stranded RNAs as 

Novel Active Compounds 

Novel Chemistries and 

PK/PD Modulation 

Oligonucleotide Delivery: 

Mechanisms and 

Emerging Strategies 

12:45 pm Networking Luncheon in Poster and Exhibit Hall (Exhibit Hall D) 

2:00 pm - 

4:15 pm 

4:15 pm - 

5:15 pm 

CMC and Analytical 

Challenges and Solutions – 

Oligonucleotide Case Studies 

(Room 302) 

Strategy Discussion Forum: 

Manufacturing: What Scale, 

When? (Room 308) 

CMC Challenges and Solutions 

– Peptide Case Studies and 

Strategies (Room 304) 

Session Sponsored by Bachem 

Emerging Technologies Showcase: 

Spotlight Presentations 

Sponsored by 

ChemGenes/ 

Prime Synthesis 

and aptaIT GmbH 

(Room 302) 

Sponsored by 

Lonza and 

Sekisui 

(Room 304) 

Technologies for Cell and 

Tissue Targeting or 

Improved Delivery 

Panel Discussion: What 

Does it Take to Bring an 

Oligonucleotide to Market? 

Novel Synthetic Approaches 

to Modify Peptides and 

Improve Drug-like Properties 

Structure-based Design of 

Novel Peptides 

Molecular Diversity and 

Novel Peptide Macrocycles 

Panel Discussion: Emerging 

Strategies for Novel Peptide 

Drug Discovery 

Regulatory, Manufacturing and 

Business Considerations 

Keynote Presentation: 

Industry Perspective on Evolving 

Regulatory Environment for IVDs 

Karen S. Long, Division Vice President, 

Medical, Regulatory and Clinical 

Affairs, Abbott Molecular, Inc. 

Audience Interactive Panel 

Discussion: Regulatory Support 

of Innovation: Navigating 

FDA’s Pathways while Developing 

Novel Technologies 


Specifications for Oligonucleotide 

and Peptide Active 

Pharmaceutical Ingredients 

(Room 313) 

New Technologies 

Panel Discussion: The Oligo 

Supply Chain for Diagnostics – 

Raw Materials for Oligo Synthesis 

– Selecting the Right Fluorophore/ 

Reporter Pair and Chemistry 

5:15 pm - 

6:15 pm Networking, Wine and Cheese Reception in Poster and Exhibit Hall Sponsored by Lonza (Exhibit Hall D) 

Wednesday, May 15, 2013 

Poster and Exhibit Hall Hours: 10:30 am – 2:00 pm 

8:00 am - 

8:30 am 

8:30 am - 

11:15 am 

11:15 am - 

12:45 pm 

Oligonucleotide and Peptide Manufacturing, Technology 









Featured Presentation: Steven F. Dowdy, Ph.D., UCSD School of Medicine (Room 311) 

Strategies for Oligonucleotide 

Process Design and Optimization 

(Room 302) 

Spotlight Presentation 

Sponsored by OctoPlus 

(Room 302) 

(ends 11:45) 

Conjugated Oligonucleotide and 

Peptide Therapeutics (Room 304) 


Conjugation: Extending the 

Therapeutic Potential of 

Oligonucleotides and Peptides 

(Room 308) 

Discovery and Preclinical 

Strategies 

12:45 pm Networking Luncheon in Poster and Exhibit Hall (Exhibit Hall D) 

1:55 pm - 

5:15 pm 

Formulation and Delivery (Room 302) 

Clinical Progress of 

Oligonucleotide Therapeutics 

Intracellular Delivery 

of Peptides 

Preclinical Strategies to Exploit 

Novel Targets and Optimize 

Properties of Peptides 

Peptides in Early Development and 

New Frontiers in Peptide R&D 

MicroRNA for Diagnostics 

www.IBCLifeSciences.com/TIDES 3

Event Sponsors 

Platinum Sponsor 

Gold Sponsors 

Silver Sponsors 

Bronze Sponsors 

Session Sponsors 

Spotlight Presentation Sponsors 

Corporate Suite Sponsors 

Badge/Lanyard Sponsor 

Totebag Sponsor 

Networking Reception Sponsors 

(Monday) 

(Tuesday) 

Event Guide Sponsor 

Literature Sponsors 

4 TIDES® Conference & Exhibition

Sunday, May 12, 2013 • Courses 

9:00 Registration and Coffee 

Course #1: 

Application of Current FDA and ICH 

Guidelines to the Manufacturing 

and Analysis of Oligonucleotides 

Room 202 

Course Leaders: 

Doug Brooks, Ph.D., Executive Director, Chemistry, Regado Biosciences 

G. Susan Srivatsa, Ph.D., President, ElixinPharma 

Fran Wincott, Ph.D., Wincott and Associates 

10:00 Overview: Application of Existing FDA/ICH Quality Guidelines to 

the Development of Oligonucleotides 


Fran Wincott, Ph.D., Wincott and Associates 

10:30 Control Strategy for Raw Materials of Oligonucleotide 

Drug Substances: Application of ICHQ11 

Claus Rentel, Ph.D., Executive Director, Analytical Development, 

Isis Pharmaceuticals, Inc. 

11:10 Acceptance Criteria and Thresholds for Impurities in 

Oligonucleotide Drug Substances and Drug Products 

James V. McArdle, Ph.D., President, McArdle & Associates 

11:50 Report from IQ Consortium Working Group 

Shiranthi Jayawickreme, Ph.D., Associate Director Technical Development, 

Biogen Idec 

12:30 Lunch on your own 

2:00 Application of Statistical Principles in ICHQ1 to Shelf Life 

Assignment of Oligonucleotides with Limited Number of Batches 

Matthias Kretschmer, Ph.D., Director, Analytical Sciences, 

Alnylam Pharmaceuticals, Inc. 

2:40 Case Study Pulling it all Together – Effectively Applying the 

Current ICH Guidelines for Method Validation, Impurities, and 

Specifications to Advance your Programs to Phase III 


3:20 Networking Refreshment Break (Boylston Hallway- 2nd Floor) 

3:40 ICH Q11: Application of QBD Principles to the Validation of 

Oligonucleotide Manufacturing Processes: Does Q11 Allow for 

Platform Validation? 

Mark C. Guzman, Ph.D., Principal, MG Consulting 

4:20 PAT Applications for Oligonucleotide Synthesis and Purification 

Peter McDonnell, Ph.D., Senior Technical Director, Genzyme 

5:00 Audience Interactive Panel Discussion 

5:30 Close of Course 

Course #2: 

Business and Operational Strategies for 

Successful Peptide Development 

Room 204 


Bruce H. Morimoto, Ph.D., Vice President, Drug Development, 

Allon Therapeutics Inc., Canada 

Gary F. Musso, Ph.D., President, Musso and Associates LLC 

10:00 Course Introduction: Strategies for Management of Manufacturing 

and Quality Control during Early Stage Development 

Michael Verlander, D.Phil., President, PolyPeptide Group (San Diego) 

10:30 Strategies for Manufacturing Success: Managing Intellectual 

Property and Know-How Challenges 

Firoz Antia, Ph.D., CMC Team Director, Pharmaceutical Operations and 

Technology, Biogen Idec 

11:10 Business Considerations for the Management of Contract 

Manufacturing to Support Multiple Development Programs; 

a Strategic Blend of DIY and Renting 

Bruce H. Morimoto, Ph.D., Vice President, Drug Development, 

Allon Therapeutics Inc., Canada 

11:50 What Does it Really Take to Scale Up Peptide Synthesis to 

50 kg Batches? 

Brad Dehoff, Ph.D., Director, R&D, Corden Pharma 


2:00 Bringing it All Together for Development, Regulatory and 

Business Success 

Gary F. Musso, Ph.D., President, Musso and Associates LLC 


3:15 CMO-Sponsor Collaboration: Aligning the Manufacturing 

Approach with the Drug Development Stage 

Mimoun Ayoub, Ph.D., Vice President, Strategic Development, 

Peptisyntha, Member Of The Solvay Group, Belgium 

4:25 Follow Up Audience Interactive Panel Discussion 



Sunday, May 12, 2013 • Courses 

9:00 Registration and Coffee 

Course #3: 

Peptide and Oligonucleotide 

Conjugation Strategies 

Course #4: 

Physicochemical Characterization of 


Room 203 


Christopher P. Holmes, Ph.D., Executive Director, Chemistry, Affymax, Inc. 

Lubomir V. Nechev, Ph.D., Vice President, Process Chemistry, 


10:00 Introduction: Why Do We Need to Conjugate Ligands 

to Oligonucleotides? 

Muthiah (Mano) Manoharan, Ph.D., Senior Vice President, Drug Discovery, 


10:30 Linkers, Ligands, Linkages and Tethers 

Kallanthotathil G. Rajeev, Director, Medicinal Chemistry, 


11:00 Click Chemistry for Oligonucleotide Conjugates 

Jayaprakash (Jay) Nair, Principal Scientist, Medicinal Chemistry, 


11:30 Application of Retro Diels Alder Chemistry to Cleavable 

Linker Technology 

Kenneth W. Hill, Ph.D., Principal Investigator, Agilent Technologies, Inc. 

12:00 Peptide Conjugated Oligonucleotides 

Scott Petersen, Ph.D., Chief Scientific Officer, Liposciences, Inc. 

12:30 Lunch on your Own 

2:00 Importance of Control Experiments to Support Product Approval 

of Conjugates 


2:30 Conjugation of Peptides: A CMOs Perspective 

Rodney Lax, Ph.D., Senior Director Business Development, 

PolyPeptide Group, North America 


3:30 Challenges of Analytical Characterization and Certification of 

Peptide Conjugates during Drug Substance Development 

Rainer Gast, Ph.D., Manager Analytical Development, PolyPeptide Group, 

North America 

4:00 Case Study Development of Enhanced PNA Delivery Systems via 

Conjugation Strategy 

Gang Shen, Ph.D., Research Scientist, Oligonucleotide Drug Development, 

OPKO Health 



Room 205 

Course Leader: Andrew Dibble, Ph.D., Director, 

Pharmaceutical Development, Isis Pharmaceuticals, Inc. 

10:00 Overview: The Importance of Physicochemical Characterization as 

Part of the Development Process 

Andrew Dibble, Ph.D., Director, Pharmaceutical Development, 


10:10 Routine Characterization (e.g., Buffering Capacity, pKa, Isoelectric 

Point, Zeta Potential, Moisture Sorption Isotherm, T-Melt) 



10:35 The Application of DSC and ITC to the Characterization of 


Hüseyin Aygün, Ph.D., Chief Scientific Officer, BioSpring GmbH, Germany 

11:05 Monitoring & Predicting Formulation Stability Using Non-Invasive 

Light Scattering 

Kevin Mattison, Ph.D., Principal Scientist – Bioanalytics, Malvern Biosciences 

11:50 Precipitation/Aggregation/Gelling/Turbidity 

Knut Langsetmo, Ph.D., Senior Scientist, Ipsen, Inc. 



12:05 Viscosity Considerations 




1:50 The Application of NMR, CD, and FT-IR to the Characterization of 


Michele DeRider, Ph.D., Lead Scientist, Catalent Pharma Solutions 

2:30 Considerations for Translation of Nanoparticle RNAi 

Therapeutic Candidates 

Martin C. Woodle, Ph.D., Co-Founder, CEO and CSO, 

Aparna Biosciences Corporation 


3:30 Case Study 1 Solubility in Therapeutic Peptide Candidate Selection 

Knut Langsetmo, Ph.D., Senior Scientist, Ipsen, Inc. 

4:00 Case Study 2 Mitigation of Viscosity and Turbidity in 

Oligonucleotide Solutions 






Monday, May 13, 2013 

Keynote Session 

Room 302/304 

7:30 Registration and Coffee (Prefunction Hall D) 

8:45 Chairman’s Opening Remarks 

Christopher P. Holmes, Ph.D., Executive Director, 

Chemistry, Affymax, Inc. 

9:00 Mipomersen: A Novel Second 

Generation Antisense Oligonucleotide 

for Treatment of the Rare Genetic 

Disorder, Homozygous Familial 

Hypercholesterolemia 

Mary P. McGowan, M.D., Senior Medical Director, 

Clinical Research, Genzyme, a Sanofi Company 

9:40 The State of Venture Capital, 

Startups, and Funding in Oligo 

and Peptide Therapeutics 

Bruce Booth, D.Phil., Partner, Life Sciences, 

Atlas Venture 

10:20 Networking Refreshment Break 

(Level 3 Boylston Hallway) 

10:50 Spherical Nucleic Acids (SNAs) 

Chad A. Mirkin, Ph.D., Professor, Chemistry, 

Northwestern University 

11:30 The Role of Drug Delivery and 

Device Technologies for 

Peptide Products 

William J. Lambert, Ph.D., Fellow, Drug Delivery 

and Device Development, MedImmune, Inc. 

12:10 Epitope Targeted, Protein Catalyzed 

Capture Agents Generated by 

In Situ Click Chemistry for 

Human Health Applications 

James R. Heath, Ph.D., Professor, 

Chemistry and Chemical Engineering, 

California Institute of Technology 


Plenary Session 

Room 302/304 

Updates on Commercialization of 

Therapeutic Candidates 

1:40 Chairman’s Remarks 

Bob D. Brown, Ph.D., CSO and Senior Vice President, Research, 

Dicerna Pharmaceuticals 

1:45 Plecanatide and SP-333, Guanylate 

Cyclase-C Agonists: A New Class of 

Drug Candidates for Treatment of 

Gastrointestinal Disorders and Diseases 

Kunwar Shailubhai, Ph.D., M.B.A., 

Chief Scientific Officer, Synergy Pharmaceuticals, Inc. 

2:15 Unpublished Data Development of Peptide 

Drug Candidates for Fast First Time in 

Man Dosing; A Biotech’s Perspective 

Torsten Malmström, Ph.D., Head of Pharmaceutical 

Development, Zealand Pharma A/S, Denmark 

2:45 Powered by KL4: A Better Treatment 

for Babies 

Russell G. Clayton Sr., D.O., Senior Vice President, 

R&D, Discovery Laboratories, Inc. 

3:15 Grand Opening of Poster and Exhibit Hall 

with Networking Refreshment Break 

(Exhibit Hall D) 

4:00 Antisense Development Portfolio Advances 

Richard S. Geary, Ph.D., Senior Vice President, 

Development, Isis Pharmaceuticals, Inc. 

4:30 Eteplirsen: One Small Step for Sarepta, 

One Giant Leap for DMD Treatment 

Jayant Aphale, Ph.D., MBA, RAC, 

Senior Vice President, Technical Operations, 

Sarepta Therapeutics 

 

5:00 Discovery and Development of GalNAc 

Conjugates for RNAi Therapeutics 

Muthiah (Mano) Manoharan, Ph.D., 

Senior Vice President, Drug Discovery, 

Alnylam Pharmaceuticals, Inc. 

5:30 Networking, Wine and Cheese Reception 

in Poster and Exhibit Hall Sponsored by: 

8 TIDES® Conference & Exhibition 

Do you have your TIDES Passport Game Card in Hand? 

Pick up your Passport game cards at the entrance of the Exhibit Hall when the hall opens on Monday at 3:15 pm. 

If you complete your Passport game card, you will be enrolled in a drawing to win some amazing prizes. 

This is your chance to win! 

$200 Gift Card – Donated by Avecia at Booth 214 

Kindle Fire – Donated by Bachem at Booth 326 

$100 Visa Gift Card – Donated by Biotage at Booth 508 

Noise-cancelling Headphones– Donated by Biotechlogic, Inc. at Booth 229 

i-Home – Donated by CEPIA Sanofi at Booth 105 

MacBook Pro with Retina Display, Samsung 50” 1080p TV, Samsung 40” 1080 TV, 

iPad Mini, iPod Touch – Donated by CS Bio & ShengNuo Group at Booth 306/120 

Kindle Fire HD – Donated by NSF Pharmalytica at Booth 114 

i-Pad Mini – Donated by Pyamid Lab– Donated by Booth 524 

IPad mini WiFi-16GB ST Pharm – Donated by Booth 428 

How to Play: 

1. Visit each booth in the exhibit hall listed in your passport. 

Each booth will be labeled as a “Passport STOP” 

2. Have each exhibiting company initial their destination on 

your passport. 

3. Turn in your passport game card at the IBC Show 

Management Booth at the back of the hall by 1:30 pm 

on Wednesday. 

4. Winners will be announced Wednesday at 1:35 pm. 

The drawing will be held in the exhibit hall. 

You must be present to win!

Tuesday, May 14, 2013 • Main Conference 

Oligonucleotide and Peptide Manufacturing, Technology and Product Development 

Room 302 



Bob Huang, Ph.D., Director, North American API Contract Manufacturing, Cepia Sanofi 

CMC Challenges and Solutions – Strategic Approaches Session Sponsored by 

8:30 Scale-up of Oligonucleotides: Principles and Pitfalls 

Peter McDonnell, Ph.D., Senior Technical Director, Genzyme, United Kingdom 

9:00 Continued Process Verification (CPV), What’s Changed in our Approach to Process Validation? 

Paul McCormac, Ph.D., Director, Biomanufacturing Sciences Group, Pfizer Global Supply 

9:30 

Unpublished Data Case Study Characterization of Oligonucleotide Biotherapeutics by LC/MS/MS 

Olga V. Friese, Ph.D., Associate Research Fellow, Biotherapeutics Analytical Research and Development, Pfizer 

10:00 Regulatory Expectations for the Quality of Oligonucleotide Products on Applications for Clinical Trials and Market Authorizations in the EU 

Axel Ståhlbom, Ph.D., Assessor Biotech, Department of Biotechnology and Pharmacy, Medical Products Agency, Sweden 

10:30 Networking Refreshment Break in Poster and Exhibit Hall 


11:15 Room 313 

11:15 Spotlight Presentation (Room 302) 

Emerging Technologies Showcase 

Specifications for Oligonucleotide and Peptide 

Active Pharmaceutical Ingredients 

Moderator: 

Daniel C. Capaldi, Ph.D., Vice President, Analytical and 

Process Development, Isis Pharmaceuticals, Inc. 

Panelists: 

Pierre Boulas, Ph.D., Director, Analytical Development, 

Biogen Idec 

Doug Brooks, Ph.D., Executive Director, Chemistry, 

Regado Biosciences 



12:15 

Axel Ståhlbom, Ph.D., Assessor Biotech, Department of 

Biotechnology and Pharmacy, Medical Products Agency 

Aleksander Swietlow, Ph.D., Principal Scientist, 

Amgen Inc. 


Sponsored by 

10 TIDES® Conference & Exhibition 

Sponsored by 

Advancements in the Bioanalyisis of Oligonucleotide Therapeutics: 

The Right Method for the Right Purpose 

Laixin Wang, Ph.D., Method Development Group Leader, Utah Facility, Tandem Labs 

11:45 11:45 Spotlight Presentation (Room 302) 

Sponsored by 

Advances and Applications of Blockmer Technology: Synthesis of NUAAP siRNA Using 

Six Dimer Phosphoramidites 

Kyeong Eun Jung, Ph.D., Director, Oligo Division, ST Pharm Co. Ltd. (former Samchully Pharm), Korea 

Selected Innovations in Peptide-based Therapeutics in the 500-5000 Da Gap 

Richard Pariza, Ph.D., President, C-NOF Pharmaceuticals, Inc. 

12:45 Networking Luncheon in Poster and Exhibit Hall










Erich Koller, Ph.D., Assistant Director Core 

Research, Isis Pharmaceuticals, Inc. 

Single Stranded RNAs as 

Novel Active Compounds 

8:30 Chemically Modified Single Stranded RNA 

Activates RNA Interference in Animals 

Thazha P. Prakash, Ph.D., Senior Research Fellow, 

Isis Pharmaceuticals 

9:00 Targeting Long Non-coding RNA Interactions 

with PRC2 to Activate Single Gene Expression 

James Barsoum, Ph.D., Chief Scientific Officer, 

RaNA Therapeutics 


Chairman’s Remarks 

Tomi K. Sawyer, Ph.D., Chief Scientific Officer and 

Senior Vice President, Aileron Therapeutics Inc. 

Novel Synthetic Approaches to 

Modify Peptides and Improve 

Drug-like Properties 

Chemoselective Approaches for Protein 

Synthesis and Bioconjugation 

Philip Dawson, Ph.D., Associate Professor, 

Department of Chemistry and Associate Dean of 

Graduate Studies, The Scripps Research Institute 

Clicking into Peptide Staples via a 

Chemoselective Cysteine Arylation 

Brad L. Pentelute, Ph.D., Assistant Professor of 

Chemistry, Massachusetts Institute of Technology 

(8:25) Chairwoman’s Remarks 

B. Melina Cimler, Ph.D., Vice President, Quality and 

Regulatory, Illumina, Inc. 

Regulatory, Manufacturing 

and Business Considerations 

Keynote Presentation: 

Industry Perspective on Evolving Regulatory 

Environment for IVDs 

Karen S. Long, Division Vice President, Medical, 

Regulatory and Clinical Affairs, Abbott Molecular, Inc. 

Patenting Genes: A Review of Myriad in the 

Shadow of Prometheus 

Peter G. Carroll, Ph.D., J.D., Founding Partner, 

Medlen and Carroll 

Novel Chemistries and 

PK/PD Modulation 

9:30 Automated Parallel Solid-phase Synthesis 

of 5’-triphosphate and 5’-diphosphate 

Oligonucleotides – Useful Tools for 

Therapeutics and Diagnostics Applications 

Ivan Zlatev, Ph.D., Scientist, Ontorii Inc. (This 

presentation will be based on work performed at Alnylam Pharmaceuticals) 


Mechanisms and Emerging Strategies 

10:00 Physical Characterization of Lipid 

Nanoparticles for Efficient Delivery of Dicer 

Substrate siRNAs to Tumors 

Bob D. Brown, Ph.D., Chief Scientific Officer 

and Senior Vice President, Research, 

Dicerna Pharmaceuticals 



Interfering Peptides Targeting 

Protein-protein Interactions 

Katja Arndt, Ph.D., Professor of Molecular 

Biotechnology, Institute for Biochemistry and 

Biology, University of Potsdam, Germany 

The Design of Cell-penetrating Peptides with 

Intrinsic Biological Activity 

Francesca Milletti, Ph.D., Head, Cheminformatics 

and Statistics, Hoffmann-La Roche 

Development and Validation of an 

Automated NGS LDT for Determining 

HIV Coreceptor Status 

A.J. Chmura, Ph.D., Staff Scientist, 

Siemens Healthcare Diagnostics 

Audience Interactive 

Panel Discussion 

Regulatory Support of Innovation: 

Navigating FDA’s Pathways while 

Developing Novel Technologies 

Moderator: 

B. Melina Cimler, Ph.D., Vice President, Quality and 

Regulatory Affairs, Illumina, Inc. 

Panelists: All morning speakers 



Mechanisms and Emerging 

Strategies (continued) 

11:15 Delivering on the Promise of Therapeutic 

Oligos: An ADME Perspective 

Steve Hood, Ph.D., Director, GSK Oligonucleotide 

Delivery (GOLD) Team, GlaxoSmithKline, 

United Kingdom 

11:45 Mechanisms of Single-stranded 

Phosphorothioate Modified 

Antisense Oligonucleotide 

Accumulation in Hepatocytes 

Erich Koller, Ph.D., Assistant Director Core 

Research, Isis Pharmaceuticals, Inc. 

12:15 RNAi Therapeutics as Personalized Medicine for 

the Treatment of Hepatocellular Carcinoma 

Mary Prieve, Ph.D., Director of Biology, PhaseRx, Inc. 



(continued) 

Structure-based Discovery of ATSP-7041, a 

Dual MDM2 and MDMX Targeting Stapled 

α-Helical Peptide Exhibiting Potency In Vitro 

and In Vivo Efficacy in Xenograft Models of 

Human Cancer 

Vincent Guerlavais, Ph.D., Senior Principal Scientist, 

Aileron Therapeutics, Inc. 

Identification of Cell-permeable Peptides 

Targeting the Wnt-pathway – Functional 

Characterization and Activity In Vivo 

Hanjo Hennemann, Ph.D., Chief Scientific Officer, 

Nexigen GmbH, Germany 

The Alphabody: At the Crossroads of 

Constrained Peptides and Small Proteins 

Ignace Lasters, Ph.D., Chief Scientific Officer, 

Complix NV, Belgium 


(Room 313) 

Specifications for Oligonucleotide and Peptide 

Active Pharmaceutical Ingredients 

Moderator: 

Daniel C. Capaldi, Ph.D., Vice President, Analytical 

and Process Development, Isis Pharmaceuticals, Inc. 

Panelists: 

Doug Brooks, Ph.D., Executive Director, Chemistry, 

Regado Biosciences 



Axel Ståhlbom, Ph.D., Assessor Biotech, 

Department of Biotechnology and Pharmacy, 

Medical Products Agency 

Aleksander Swietlow, Ph.D., Principal Scientist, 

Amgen Inc. 

12:45 Networking Luncheon in Poster and Exhibit Hall 




Room 302 Room 304 


Edward Huber, Ph.D., Director, Quality Control and Analytical Development, 

Avecia 

CMC and Analytical Challenges and Solutions – 

Oligonucleotide Case Studies 

2:00 Rapid 2-D UHPLC for In-process Control of 

Oligonucleotide Impurities 

Todd B. Kreutzian, Director, Analytical Development, Agilent Technologies, Inc. 


Brian Gregg, MBA, General Manager, Bachem Americas, Inc. 

CMC Challenges and Solutions – 

Peptide Case Studies and Strategies 

Session Sponsored by 

Featured Presentation: 

Regulatory Considerations for Peptide Cancer Vaccines 

Michail A. Alterman, Ph.D., Senior Investigator, Tumor Vaccines and 

Biotechnology Branch, Division of Cellular and Gene Therapies, Center for 

Biologics Evaluation and Research, US FDA 

2:30 Active Statistical Process Control of the AV7909 

Production Process 

Richard W. Welch, Ph.D., Vice President, Process and Analytical Development, 

BioDefense Division, Emergent BioSolutions 

BLP25 – A MUC1 Peptide Used in Development of an 

Immunotherapy for Non-Small Cell Lung Cancer 

Christian Schröter, Ph.D., Site Director, EMD Serono, a Division of EMD Inc., 

Canada 

3:00 Advantages and Disadvantages Related to Use of Quantitative 

LC/MS Methods for Routine QC Testing 

Edward Huber, Ph.D., Director, Quality Control and Analytical Development, 

Avecia 

Synthetic Manufacturing of Glucagon 

Thomas Meier, Ph.D., Vice President, Production, Bachem AG, Switzerland 



(Room 308) 

4:15 Manufacturing: What Scale, When? 

Moderator: 

Rodney Lax, Ph.D., Senior Director, Business 

Development, PolyPeptide Group (Torrance) 


Sponsored by 

Panelists: 

HybCPG- A New Solid Phase 

Oligosynthesis Support 

Angelika Fretzen, Ph.D., Vice President, 

Marc Rothstein, President, Prime Synthesis, Inc. 

Pharmaceutical Chemistry and Development, 

Suresh C. Srivastava, Ph.D., President, 

Ironwood Pharmaceuticals, Inc. 

ChemGenes Corp. 

4:45 

Paul McCormac, Ph.D., Director, Biomanufacturing 

Sciences Group, Pfizer Global Supply 

Christian Schröter, Ph.D., Site Director, 

EMD Serono, a Division of EMD Inc., Canada 


Sponsored by 

Bringing Light into the Black Box of in vitro 

Brant Zell, Vice President and Global Director, Selection Experiments: Early and Improved 

Quality, PolyPeptide Group 

Identification of Ligands by in silico Analysis 

Kevin Fettes, Ph.D., Director, Manufacturing and of Next-Generation Sequencing Data 

CMC, Galena Biopharma 

Michael Blank, Ph.D., Chief Scientific Officer, 

aptaIT GmbH, Germany 

Emerging Technologies Showcase 

4:15 Unpublished Data Case Study (Room 304) 

Recent Developments in Liquid Phase Peptide 

Synthesis: Application to Large Scale Production 

El Djouhar Rekaï, Upstream Process Group Leader, 

Operations, Lonza, Belgium 


Sponsored by 

Molecular Hiving Technology: New LPPS 

Technology TM for cGMP Manufacturing 

Barry O’Connor, Ph.D., R&D Group, Iwate Research 

& Development Center, Pharmaceuticals & Fine 

Chemicals Division, Pharma & Research Business, 

Sekisui, Japan 

5:15 Networking, Wine and Cheese Reception in Poster and Exhibit Hall Sponsored by 

Dedicated Poster Viewing – Poster presenters will be at their posters to discuss results with you. 











Martin Maier, Ph.D., Senior Director, RNA 

Synthesis, Alnylam Pharmaceuticals 

Technologies for Cell and Tissue 

Targeting or Improved Delivery 

(continued) 

2:00 Lipid Nanoparticle siRNA Systems: 

Gene Silencing in Non-liver Tissues 

Pieter R. Cullis, Professor and Director, 

Nanomedicines Research Group, Department of 

Biochemistry and Molecular Biology, University of 

British Columbia, Canada 

2:30 Combinatorial Development of 

Synthetic siRNA Delivery Systems 

Daniel G. Anderson, Ph.D., Associate Professor 

Chemical Engineering, Koch Institute, 

Massachusetts Institute of Technology 

3:00 Development of DPC Technology for 

Therapeutic siRNA Delivery 

David Lewis, Ph.D., Vice President, Biology, 

Arrowhead Research Corporation 




Molecular Diversity and 

Novel Peptide Macrocycles 

Plant-based Production of Orally Active 

Macrocyclic Peptides 

David Craik, Ph.D., Professor of Biomolecular 

Structure, Institute for Molecular Bioscience 

University of Queensland, Australia 

New Strategies for Peptide Macrocyclization 

Andrei Yudin, Ph.D., Founder, Encycle Therapeutics 

and Professor of Chemistry, University of Toronto, 

Canada 

Macrocycles for Drug Discovery – 

Identification of Small Molecule Synthetic 

Macrocycle Antagonists of Human IL17A 

Nick Terrett, PhD., Chief Scientific Officer, 

Ensemble Therapeutics Corp. 



4:15 What Does it Take to Bring an 

Oligonucleotide to Market? 

Moderator: 

Arthur A. Levin, Ph.D., Executive Vice President, 

R&D, Miragen Therapeutics 

Panelists: 

Ian MacLachlan, Ph.D., Executive Vice President 

and Chief Scientific Officer, 

Tekmira Pharmaceuticals Corp. 

Rachel Meyers, Ph.D., Vice President Research and 

RNAi Lead Development, Alnylam Pharmaceuticals 

Hans-Peter Vornlocher, Ph.D., Managing Director 

Research, Axolabs GmbH, Germany 

Molecular Diversity and Novel 

Peptide Macrocycles (continued) 

Bi-cyclic Peptides to Target Protein-protein 

Interactions 

Christophe Bonny, Ph.D., Chief Scientific Officer, 

Bicycle Therapeutics, United Kingdom 


4:45 Emerging Strategies for Novel Peptide 


Moderator: 



Panelists: 

David Craik, Ph.D., Professor of Biomolecular 

Structure, Institute for Molecular Bioscience, 

University of Queensland, Australia 

Hanjo Hennemann, Ph.D., Chief Scientific Officer, 

Nexigen GmbH, Germany 

Francesca Milletti, Ph.D., Head, Cheminformatics 

and Statistics, Hoffmann-La Roche 

Nick Terrett, Ph.D., Chief Scientific Officer, 

Ensemble Therapeutics Corp. 

5:15 Networking, Wine and Cheese Reception in Poster and Exhibit Hall Sponsored by 

Dedicated Poster Viewing – Poster presenters will be at their posters to discuss results with you. 


Thomas Battersby, Ph.D., Senior Manager, 


New Technologies 

Unpublished Data Single Molecule 

Electronic DNA Sequencing by Synthesis 

Jingyue Ju, Ph.D., Samuel Ruben-Peter G. Viele 

Professor of Engineering Professor of Pharmacology 

and Chemical Engineering; Director, Center for 

Genome Technology and Biomolecular Engineering, 

Columbia University 

Sensitive Detection and Profiling of Cancer 

Cells Using Oligonucleotide-barcode Magnetic 

Nanoparticles and microNMR Sensors 

Hakho Lee, Ph.D., Assistant Professor, 

Biomedical Engineering, Center for Systems Biology, 

Harvard Medical School 

Unpublished Data Novel High-Affinity DNA 

Aptamers by in vitro Selection Using an 

Unnatural Base Pair System 

Ichiro Hirao, Ph.D., Team Leader/CEO, 

RIKEN / TagCyx Biotechnologies, Japan 

Audience Interactive 


The Oligo Supply Chain for Diagnostics - 

Raw Materials for Oligo Synthesis – 

Selecting the Right Fluorophore/Reporter 

Pair and Chemistry 

Moderator: 

Dick Keys, Ph.D., President, Advanced Biotectonics 

Consulting 

Panelists: 

Jessica Alexander, VP Specialty Manufacturing, 

Integrated DNA Technologies 

Chad Gerber, Director, GMP Manufacturing and 

Commercial Services, Biosearch Technologies, Inc. 

Andrei Laikhter, Ph.D., Chief Scientific Officer, 

ChemGenes Corporation 

Catherine McKeen, Ph.D., Technical Manager, 

Link Technologies Ltd., United Kingdom 

Premier Publication: 

Media Partners: 

Event Partner: 


Wednesday, May 15, 2013 • Main Conference 


7:30 Coffee (Prefunction Hall D) 

8:00 Featured Presentation (Room 311): Unpublished Data Tackling RNAi Delivery with Bioreversible PhosphoTriester siRNN Prodrugs 

Steven F. Dowdy, Ph.D., UCSD School of Medicine 


John DeMattei, Ph.D., Director of Chemical Development, Nucleic Acid Solutions 

Division, Agilent Technologies, Inc. 

Strategies for Oligonucleotide 

Process Design and Optimization (Room 302) 

8:30 Design Space Understanding to Lock Process for a Late Phase 

RNA Molecule 

Satya Kuchimanchi, Ph.D., Associate Director, RNAi Lead Development, 





Conjugated Oligonucleotide 

and Peptide Therapeutics (Room 304) 

Understanding the Objectives: Why Do We Conjugate? 

Rory F. Finn, Principal Scientist, Bioprocess R&D, Biotherapeutics 

Pharmaceutical Sciences, Pfizer Inc. 

9:00 Spotlight Presentation 

Sponsored by 

QbD: Building Quality into Oligo Processes at the Early 

Development Stage 

John DeMattei, Ph.D., Director of Chemical Development, Nucleic Acid Solutions 

Division, Agilent Technologies, Inc. 

9:30 

Unpublished Data Case Study 

Manufacturing Scale-Up Considerations for the REG1 System 

Doug Brooks, Ph.D., Executive Director Chemistry, Regado Biosciences 

Peptide Conjugation: A Novel Platform for Intracellular Delivery 

Paolo Botti, CEO and CSO, ArisGen, Switzerland 

Developing Process for Manufacture of GalNAc 

Conjugated Oligonucleotides 

Ligang Zhang, Principal Scientist, Process Chemistry, Alnylam Pharmaceuticals 

10:00 OligoFrag 1.0 - A Software for Rapid Impurity Profiling – Enabling 

Faster Process Development and Understanding 

Susann Rosmus, Ph.D., Head of Quality Management, BioSpring GmbH, 

Germany 


11:15 

Spotlight Presentations 

Sponsored by (11:15-11:45) 

Development of Scalable Processes for Lipid Nano-particulates 

at OctoPlus (Room 302) 

Gert-Jan Ottjes, Senior Engineer Formulation and Process Development, 

OctoPlus N.V., The Netherlands 

Unpublished Data Co-injection of a Targeted, Reversibly Masked 

Endosomolytic Polymer Dramatically Improves the Efficacy of 

Small Interfering 

RNA-Conjugates In Vivo 

David B. Rozema, Ph.D., Vice President, Chemistry, 

Arrowhead Research Corporation 


Conjugation: Extending the Therapeutic Potential 

of Oligonucleotides and Peptides (Room 308) 

Moderators: 

Rory F. Finn, Principal Scientist, Bioprocess R&D, Biotherapeutics 

Pharmaceutical Sciences, Pfizer Inc. 



Panelists: 


Martin Maier, Ph.D., Senior Director, RNA Synthesis, Alnylam Pharmaceuticals 

Muthiah (Mano) Manoharan, Ph.D., Senior Vice President, Drug Discovery, 

Alnylam Pharmaceuticals 










7:30 Coffee (Prefunction Hall D) 

8:00 Featured Presentation (Room 311): Unpublished Data Tackling RNAi Delivery with Bioreversible PhosphoTriester siRNN Prodrugs 

Steven F. Dowdy, Ph.D., UCSD School of Medicine 


Troels Koch, Ph.D., Vice President, Research and 

CTO, Santaris Pharma A/S, Denmark 

Discovery and 

Preclinical Strategies 

8:30 Novel Chemical Modifications for siRNAs 

Martin Maier, Ph.D., Senior Director, RNA 

Synthesis, Alnylam Pharmaceuticals 

9:00 Efficacy, PK and Tox Data Supporting the 

Move to IND for Mirna Therapeutics 

David Brown, Ph.D., Director of Discovery, 

Mirna Therapeutics 

9:30 Nucleic Acid Polymers and Their Application 

in Hepatitis B Infection (HBV): Efficacy 

and Safety 

Andrew Vaillant, Ph.D., Vice President and Chief 

Scientific Officer, REPLICor Inc., Canada 

10:00 Therapeutic Opportunities for Interferon 

Regulatory Factor 5 (IRF5) Antisense 

Inhibitors in Systemic Lupus 

Erythematosus (SLE) 

Alexey Revenko, Ph.D., Senior Scientist, 

Isis Pharmaceuticals 



Jesse Z. Dong, Ph.D., Vice President, 

Compound Discovery, IPSEN 

Intracellular Delivery of Peptides 

Intracellular Delivery of Peptides – An 

Overview from the Perspectives of Pharma 

Thomas Vorherr Ph.D., Director Peptide Discovery, 

Novartis Pharma AG, Switzerland 

(9:10) Cellular Peptide Delivery – Exploration 

of Structure Space 

Roland Brock, Ph.D., Head, Department of Biochemstry, 

Nijmegen Centre for Molecular Life Sciences, Radboud 

University Nijmegen Medical Centre, The Netherlands 

Preclinical Strategies to Exploit 

Novel Targets and Optimize 

Properties of Peptides 

(9:50) Exploiting Disulfide-rich Peptides in 


Mark Smythe, Ph.D., Founder, 

Protagonist Therapeutics 


MicroRNA for Diagnostics 

(8:55) Chairman’s Remarks 



Unpublished Data Development and 

Characterization of a Rapid Pathogen 

Capture System for Direct Isolation of 

Microorganisms from Blood 

Sergey A. Dryga, Ph.D., MBA, Vice President, 

Immunochemistry, NanoMR, Inc. 

Automated microRNA Assays for Tissue-based 

Diagnostics 

Lorenzo F. Sempere, Ph.D., Research Assistant 

Professor of Medicine, Geisel School of Medicine 

at Dartmouth 

MicroRNA in Biofluids: Robust Biomarkers 

for Disease 

Peter Mouritzen, M.Sc., Ph.D., VP Research and 

Development, Exiqon A/S, Denmark 

11:15 Structure Activity Determinants of Locked 

Nucleic Acids: Platform, Discovery, Clinic 

Troels Koch, Ph.D., Vice President, Research and 

CTO, Santaris Pharma A/S, Denmark 

Phenotypic Screening of Phylomer Libraries 

to Discover and Validate Targets Using 

“Protein Interference” 

Paul Watt, Ph.D., Non-Executive Director, 

Phenomica; CEO, Phylogica, Australia 

Plasma microRNAs Serve as Biomarkers of 

Therapeutic Efficacy and Disease Progression 

in Hypertension-Induced Heart Failure 

Brent A. Dickinson, Research Scientist, Biology, 

miRagen Therapeutics, Inc. 

11:45 Intervening in Complex Disease Biology with 

microRNA Targeting Therapeutics 

William S. Marshall, Ph.D., President and Chief 

Executive Officer, miRagen Therapeutics 

12:15 Targeting microRNAs and Biological 

Networks: An Innovative Approach to 

Treat Disease 

Neil Gibson, Ph.D., Chief Scientific Officer, 

Regulus Therapeutics 

(11:50) Peptide Lead Optimization using 

Solid-phase Peptide Arrays 

Peter Timmerman, Ph.D., Chief Technology Officer, 

Pepscan Therapeutics, The Netherlands 

microRNA-Associated Progression Pathways 

and Potential Therapeutic Targets Identified 

by Integrated mRNA and microRNA 

Expression Profiling in Breast Cancer 

Ioannis (Jiannis) Ragoussis, Ph.D., Head of 

Genome Sciences, Associate Professor in Human 

Genetics, McGill University and Génome Québec 

Innovation Centre, Canada 

Circulating miRNA Biomarkers: 

An Industrial Perspective 

Pavan Kumar, Ph.D., Senior Scientist, Biomarkers 

and Personalized Medicine, Eisai Inc. 



Oligonucleotide and Peptide 

Manufacturing, Technology 







1:55 Chairman’s Remarks: Overcoming 

Challenges in Formulation and Delivery 

Ved Srivastava, Ph.D., Head, Peptide Chemistry, 

GlaxoSmithKline 



Bo Rode Hansen, Vice President, Santaris Pharma 

A/S, Denmark 


Thomas Vorherr Ph.D., Director Peptide Discovery, 

Novartis Pharma AG, Switzerland 

Formulation and Delivery 

Clinical Progress of 

Oligonucleotide Therapeutics 

Peptides in Early Development and 

New Frontiers in Peptide R&D 

2:15 

2:45 

Unpublished Data 

Techniques for Assessing Aggregation of 

Peptides and Nucleic Acids 

John Philo, Ph.D., Vice President, 

Alliance Protein Laboratories, Inc. 

Unpublished Data Case Study Prospects in 

Developing Injectable Peptide Drug Products 

Farooq Z. Qureshi, Ph.D., Senior Principal Scientist, 

Research Leader, Pharmaceutical and Analytical 

R&D, Hoffmann-La Roche Inc. 

Update on Alnylam Clinical Programs 

Akshay Vaishnaw, M.D., Ph.D., 

Executive Vice President, Chief Medical Officer, 

Alnylam Pharmaceuticals 

Inhibition of Toll-like Receptors as a Strategy 

for Treating Autoimmune Diseases 

Sudhir Agrawal, CEO, Idera Pharmaceuticals, Inc. 

3:15 Networking Refreshment Break (Level 3 Boylston Hallway) 

First Non-hormonal Therapeutic Candidate 

for Endometriosis 

Vinay K. Singh, Ph.D., Assistant Professor, 

Department of Biomedical and Molecular Sciences, 

Queen’s University, Canada 

ShK-186 from Discovery to 

Clinical Development 

Michael Pennington, Ph.D., President and COO, 

Peptides International 

3:45 

Unpublished Data Case Study Update on 

State of the Art: Lipid-Based Delivery for 

Oligonucleotide-Based Therapeutics 

Ian MacLachlan, Ph.D., Executive Vice President and 

Chief Scientific Officer, Tekmira Pharmaceuticals 

Corp., Canada 

Clinical Development of RXI-109 to 

Reduce Dermal Scarring 

Pamela Pavco, Ph.D., Chief Development Officer, 

RXi Pharmaceuticals 

From Discovery to the Clinic: 

Applications of Protein Epitope Mimetics 

Daniel Obrecht, Ph.D., Chief Scientific Officer, 

Polyphor, Switzerland 

4:15 

Unpublished Data Case Study 

Scale-up of Lipid-based Delivery Systems for 

Oligonucleotides 

Violetta Akopian, Ph.D., Director, Quality 

Management, Nitto Denko Technical Corp. 

First Clinical Phase IIa Data of the Mirror- 

Image RNA Oligonucleotide NOX-A12 

Sven Klussmann, Ph.D., Chief Scientific Officer, 

NOXXON Pharma AG, Germany 

Accurate In Vivo Cancer Identification Using 

Protease-triggered Fluorescent Peptides 

Jesus “Tito” Gonzalez, Ph.D., Chief Scientific 

Officer, Avelas Biosciences 

4:45 

Unpublished Data 

Peptide Delivery: What’s the Present Status 

and What Does the Future Hold? 

Joel Richard, Ph.D., Vice President, Peptides CMC 

and Engineering, Ipsen, France 

A Synthetic, Chemically Modified siRNA 

Targeting Caspase-2 as a Therapeutic Agent 

for Ocular Neuroprotection 

Elena Feinstein, M.D., Ph.D., Chief Scientific 

Officer, Quark Pharmaceuticals, Israel 

Peptides for Diagnostic Imaging 

and Targeted Radionuclide Therapy: 

A Theranostic Approach 

Ulrich Reineke, Ph.D., CEO and Co-Founder, 

3B Pharmaceuticals, Germany 

5:15 Close of TIDES Safety, Pharmacokinetics and 

Pharmacodynamics of PNT2258 

(An anti-BCL2 DNA Targeted Drug) in 

Patients with Advanced Solid Tumors 

Wendi V. Rodrigueza, Ph.D., CSO and VP, 

Product Development, ProNAi Therapeutics, Inc. 

5:45 Close of TIDES 

Close of TIDES 

Private Meeting Rooms/Receptions (by invitation only) 

Peptisyntha ...................................Room 201 

Senn Chemicals Private Reception .............Room 202 

Thermo Scientific. .............................Room 203 

Cepia Sanofi. ..................................Room 204 

ChemGenes ...................................Room 205 

Agilent Technologies Inc. ................ Rooms 206, 301 

Avecia. ........................................Room 209 

SAFC ..........................................Room 307 

Bachem’s Private 

Reception .....Independence Ballroom 2F, Sheraton Hotel 


See You Next Year! 

May 12-15, 2014 

Rhode Island Convention Center • Providence, RI 


Meeting and Exhibit Room Map 

2nd Level 

Exhibit 

Hall D 

Conference and Exhibit Registration 

Session Rooms 

207 208 209 210 

201 202 203 204 205 W 

M 206 

Courses/Private Meeting Rooms/Receptions 

Boylston Hallway 

3rd Level 

302 304 306 309 


Manufacturing, Technology 


Peptide Manufacturing, 

Technology and 

Product Development 

Session Rooms 

Peptide 

Discovery and 

Development 

310 311 

Nucleic Acids 

Technologies for 

Molecular 

Diagnostics 



312 

301 303 305 307 

308 313 

Strategy 

Discussion 

Forums 

W 

M 

Strategy 

Discussion 

Forums 

Private Meeting Rooms/Receptions 

Boylston Hallway 


Poster and Exhibit Hall Hours 

Monday, May 13 • 3:15 pm - 6:45 pm 

Tuesday, May 14 •10:30 am - 6:15 pm 

Wednesday, May 15 • 10:30 am - 2:00 pm 

Exhibit Hall 

O : Oligo-Focused 

P : Peptide-Focused 

D : Diagnostics-Focused 

AAPPTEC LLC ...................... 109 P 

Advanced ChemTech 

(A Division of CreoSalus) ........... 526 P 

Agilent Technologies, Inc............. 314 O 

AIC/Tedia .......................... 330 O 

Ajinomoto Co., Inc. ................. 221 P 

Almac.............................. 226 P 

AmbioPharm ....................... 429 P 

American Peptide Company, Inc. . . . 325 P 

Asahi Kasei Bio Process .............. 409 O P 

Avecia ............................. 214 O 

Bachem............................ 326 P 

BCN Peptides........................ 520 P 

Berry & Associates.................. 426 O 

Bioautomation Inc. .................. 406 O 

BiOptix............................. 228 O D 

Biosearch Technologies. ............. 206 O D 

BioSpring GmbH .................... 421 O 

Biotage ............................ 508 P 

Biotechlogic, Inc. ................... 229 O 

Boston Open Labs ................. 514 O P 

Buchiglas USA Corp ................ 119 O P 

Carbosynth ........................ 430 P D 

CBL Bio Pharma .................... 510 P 

CEM Corporation ................... 230 P 

CEPIA Sanofi ....................... 105 O P 

ChemGenes........................ 220 O D 

Corden Pharma International ...... 205 P 

CPC Scientific Inc................... 210 P 

CS Bio Co........................... 306 P 

Exiqon . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 106 O 

GE Healthcare Life Sciences ........ 519 O 

GeneDesign, Inc. ................... 110 O 

Glen Research...................... 407 O 

Grace Discovery Sciences .......... 525 P 

Honeywell Burdick & Jackson ...... 225 O 

Hongene Biotechnology Ltd........ 227 O 

Hybio Pharmaceutical............... 327 P 

Intavis, Inc. ......................... 513 O P 

Irvine Pharmaceutical Services, Inc . 505 O P D 

JenKem Technology................ 232 O P D 

Kinovate Life Sciences.............. 208 O 

Lonza .............................. 320 O P 

Mallinckrodt Pharmaceuticals ...... 213 O P 

Medimetrics ....................... 515 P D 

121 

119 

111 

109 

107 

105 

231 

229 

227 

225 

232 

230 

228 

226 

120 

221 

220 

219 

116 

114 

110 

108 

106 

329 

327 

325 

328 

326 

Entrance 

330 431 

429 

322 

320 

213 214 314 

209 

205 

210 

208 

206 

309 

305 

Metkinen Chemistry ............... 425 O 

NOF Corporation................... 432 O P D 

Novasep, Inc ....................... 209 P 

NSF Pharmalytica, 

Part of NSF Health Sciences ........ 114 O 

PCAS BioMatrix Inc. ................ 410 P 

Peptisyntha S.A..................... 329 P 

Phenomenex ...................... 405 O P D 

PolyPeptide Group ................. 305 P 

PPD................................ 111 O P D 

Prime Synthesis, Inc. ............... 310 O 

Protein Technologies, Inc........... 427 O P 

PYRAMID Laboratories, inc.......... 524 O P 

310 

306 

427 

425 

421 

419 

409 

407 

405 

432 

430 

428 

426 

IBC 

Show 

Mgt. 

527 

420 519 

416 

414 

410 

406 

525 526 

515 

513 

509 

507 

505 

524 

522 

520 

516 

514 

512 

510 

508 

Quanta BioDesign, Ltd.............. 509 P D 

SAFC............................... 309 O D 

Scino Pharm Taiwan, Ltd. ........... 328 P 

Sekisui ............................. 516 P 

Shanghai SoHo-Yiming 

Pharmaceuticals Co., Ltd............ 322 P 

Shengnuo Peptide ................. 120 P 

ST Pharm Co., Ltd. .................. 428 O 

Sussex Research Laboratory, Inc. ... 219 O P D 

Thermo Scientific ..............414, 416 O 

Tosoh Bioscience................... 420 O 

TriLink BioTechnologies, Inc......... 512 O 

Waters Corporation ................ 419 O P D 


2013 Scientific Advisory Committees 


Kathryn L. Ackley, Ph.D., Senior Director 

Cincinnati Operations, Avecia 

Firoz Antia, Ph.D., CMC Team Director, 

Pharmaceutical Operations and Technology, 

Biogen Idec 

Mimoun Ayoub, Ph.D., Vice President, 

Global Business, Sales and Strategic Development, 

Peptisyntha, Member Of The Solvay Group, 

Belgium 

Neil H. Baine, Ph.D., Executive Director, 

Scinovo, Preclinical Development, 

GlaxoSmithKline Pharmaceuticals 

Doug Brooks, Ph.D., Executive Director, 

Chemistry, Regado Biosciences 

Bob D. Brown, Ph.D., Senior Vice President, 

Research, Dicerna Pharmaceuticals 

Uditha deAlwis, Senior Director, 

Analytical Sciences, Avecia 

Andrew Dibble, Ph.D., Director, Pharmaceutical 

Development, Isis Pharmaceuticals, Inc. 

Alex Fässler, Ph.D., President and COO, Bachem 

Americas Inc. 

Thomas Forman, Advisor Project Management, 

Project Management, Eli Lilly and Co. 

Mark Francis, MRSC, CChem, Csi, Director, 

Formulation Process and Analysis, UK, 

GlaxoSmithKline, United Kingdom 

Peter Hoffmann, Ph.D. 



Troels Koch, Ph.D., Vice President and CTO, 

Santaris Pharma A/S, Denmark 

Rodney Lax, Ph.D., Senior Director, Business 

Development, PolyPeptide Group (Torrance) 

Zhen Li, Ph.D., Director, Chemistry, 

Merck Research Laboratories 

David Litzinger, Ph.D., Director, Formulations 

Development, Allergan, Inc. 

Derek Maclean, Process Engineer, Amgen 

Bing Mao, Ph.D., Associate Director, Process 

Research, Merck & Co., Inc. 

John P. Mayer, Ph.D., Senior Research Scientist, 

Department of Chemistry, Indiana University 

Paul McCormac, Ph.D., Director, 

Biomanufacturing Sciences Group, 

Pfizer Global Supply 

Michael McGinley, Bioseparations Product 

Manager, Phenomenex 

Paul Metz, Senior Director, Manufacturing 

Operations, Agilent Technologies, Inc. 

Bruce H. Morimoto, Ph.D., Vice President, 

Drug Development, Allon Therapeutics Inc., 

Canada 

Gary F. Musso, Ph.D., President, 

Musso and Associates LLC 

Lubomir V. Nechev, Ph.D., Vice President, 

Process Chemistry, Alnylam Pharmaceuticals, Inc. 

Rodney Parsons, Ph.D., Group Director, 

Chemical Development, Bristol-Myers Squibb 

El Djouhar Rekai, Ph.D., Upstream Group Leader, 

Lonza, Belgium 

Claus Rentel, Ph.D., Executive Director, 

Analytical Development Quality Control, Isis 

Pharmaceuticals 

Christopher A. Rhodes, Ph.D., President, 

Christopher A Rhodes & Associates LLC 

G. Susan Srivatsa, Ph.D., President, ElixinPharma 

James D. Thompson, Ph.D., Vice President, 

Pharmaceutical Development, 

Quark Pharmaceuticals, Inc. 

David Tumelty, Ph.D., Associate Director, 

Chemistry, BioTherapeutics R&D, Pfizer Inc. 

Fran Wincott, Ph.D., President, 

Wincott & Associates, LLC 



David Brown, Ph.D., Director of Discovery, 

Mirna Therapeutics 

Elena Feinstein, M.D., Ph.D., Chief Scientific 

Officer, Quark Pharmaceuticals, Inc., Israel 

Troels Koch, Ph.D., Vice President, 

Research and Chief Technology Officer, 

Santaris Pharma, Denmark 

Satya Kuchimanchi, Ph.D., 

Associate Director, RNAi Lead Development, 


Muthiah (Mano) Manoharan, Ph.D., 

Senior Vice President, Drug Discovery, 


Pamela Pavco, Ph.D., Chief Development 

Officer, RXi Pharmaceuticals 

Dmitry Samarsky, Ph.D., 

Executive Vice President, Technology 

Development, Guangzhou RiboBio Co. Ltd, 

China 

Peptide Discovery and 

Development 

Jesse Z. Dong, Ph.D., Vice President, 

Compound Discovery, IPSEN 

Hanjo Hennemann, Ph.D., Chief Scientific 

Officer, Nexigen GmbH, Germany 

Derek Maclean, Ph.D., Director, 

Process Engineering, Amgen 

Tomi K. Sawyer, Ph.D., 

Chief Scientific Officer and Senior Vice 

President, Aileron Therapeutics Inc. 

Peter Timmerman, Ph.D., Chief Technology 

Officer, Pepscan Therapeutics, The Netherlands 

David Tumelty, Ph.D., Associate Director 

Chemistry, BioTherapeutics R&D, CovX, Pfizer 

Thomas Vorherr, Ph.D., Director, Peptide 

Discovery, Novartis Pharma AG, Switzerland 

Paul Watt, Ph.D., CEO, Phylogica, Ltd, 

Australia 





B. Melina Cimler, Ph.D., Vice President, 

Quality and Regulatory, Illumina, Inc. 

Dick Keys, Ph.D., President, 

Advanced Biotectonics Consulting 

Michael McGinley, Bioseparations Product 

Manager, Phenomenex 



2013/2014 Life Science Events 

May 2013 

Cell Line Development & Engineering 

May 20-22, 2013 

Hyatt Regency La Jolla at Aventine • La Jolla, CA 

www.IBCLifeSciences.com/CellLine 

Medicaid Managed Care Congress 

May 20-22, 2013 • Baltimore Marriott Inner Harbor at 

Camden Yards • Baltimore, MD 

www.MMCCongress.com 

June 2013 

Single-Use Applications 

for Biopharmaceutical Manufacturing 

June 3-5, 2013 • Durham Convention Center • Durham, NC 

www.IBCLifeSciences.com/SingleUse 

Vaccine Development 

& Production Summit 

June 3-5, 2013 • Durham Convention Center • Durham, NC 

www.IBCLifeSciences.com/Vaccines 

Applications for Enzyme Technologies 

June 17-18, 2013 

Hotel Nikko San Francisco • San Francisco, CA 

www.IBCLifeSciences.com/Enzyme 

Bioprocess Training Academy 

June 12-13, 2013 

Le Méridien Cambridge-MIT • Cambridge, MA 

www.IBCLifeSciences.com/Courses 

Pharmaceutical Manufacturer’s 

Gross-to-Net Accounting Forum 

June 17-18, 2013 • Hyatt Harbor Side • Boston, MA 

www.grosstonetforum.com 

Oncology Management Summit 

June 17-18, 2013 • The Wit Hotel • Chicago, IL 

www.oncologymanagementsummit.com 

Next Generation 

Protein Therapeutics Summit 

June 26-28, 2013 • Hotel del Coronado • Coronado, CA 

www.IBCLifeSciences.com/ProteinSummit 

Bioconjugates: from Targets to 

Therapeutics 

June 26-28, 2013 • Hotel del Coronado • Coronado, CA 

www.IBCLifeSciences.com/Bioconjugates 

August 2013 

BioProcess International 

Conference & Exhibition CHINA 

August 20-21, 2013 

Grand Hyatt Shanghai • Shanghai, China 

www.IBCLifeSciences.com/BPIChina 

September 2013 

Medicaid Drug Rebate Programs Summit 

September 9-11, 2013 

Chicago Marriott Downtown • Chicago, IL 

www.medicaiddrugrebates.com 

BioProcess International 

Conference & Exhibition 


Hynes Convention Center • Boston, MA 

www.IBCLifeSciences.com/BPI 

Formulation and Delivery Strategies for 

Biologics and Protein Therapeutics 



www.IBCLifeSciences.com/Formulation 

ePharma Summit West 

September 16-18, 2013 • Hyatt Regency • San Francisco, CA 

www.epharmawest.com 

Clinical Collaboration Congress 


Seaport World Trade Center • Boston, MA 

www.clinicalcollaborationcongress.com 

Biorepositories & Sample 

Management Conference 


Seaport World Trade Center • Boston, MA 

www.biorepositoriesevent.com 

Business of Biosimilars & Generic Drugs 

September 2013 • Boston, MA 

www.biosimilarsevent.com 


2013/2014 Life Science Events 

October 2013 

Bioassays and Bioanalytical 

Method Development 

October, 2013 • The Wigwam • Phoenix, AZ 

www.bioassaysevent.com 

Well Characterized Biologicals 

October 21-23, 2013 • L’Enfant Plaza Hotel • Washington DC 

www.IBCLifeSciences.com/WCB 

Product and Process Variants & Impurities 

Oct 21-22, 2013 • L’Enfant Plaza Hotel • Washington DC 

www.IBCLifeSciences.com/Variants 

Cell Therapy Bioprocessing 

Co-Located with IBC’s Inaugural Conference on: 

Gene Therapy Bioprocessing 

October 21-22, 2013 • Bethesda Marriott • Bethesda, MD 

www.IBCLifeSciences.com/CTB 

November/December 2013 

Antibody Engineering & Therapeutics 

December 8-12, 2013 

Hyatt Regency Huntington Beach Resort & Spa 

Huntington Beach, CA 

www.IBCLifeSciences.com/AntibodyEng 

January/February/March 2014 

Drug Delivery Partnerships 

January 27-29, 2014 • Boca Raton, FL 

www.drugdeliverypartnerships.com 

Flexible Facilities 

February 20-21, 2014 • Claremont Resort and Spa • Berkeley, CA 

www.IBCLifeSciences.com/Facilities 

Biopharmaceutical Development 

& Production Week 

March 24-28 2014 • The Hilton Bayfront Hotel • San Diego, CA 

www.IBCLifeSciences.com/BDPWeek 

Organized by: 

Plus: The Only Event in Japan with Comprehensive Coverage of 


IBC’s 6th Annual 

February 25-27, 2014 

Sheraton Miyako Hotel 

Tokyo, Japan 


Ranked the #1 BioProcessing Event by the Industry for 10 Years Running 

Featuring 200+ Speakers, 150+ Exhibitors and 1500+ Attendees Providing You More 

Content, Networking and Business Opportunities than Any Other Event on the Market 

Conference: September 16-19, 2013 

Exhibition: September 17-19, 2013 


Where Industry Connects to Share Technical, Scientific and 

Strategic Solutions Across All Phases of Bioprocess Development 

Upstream 

Processing 

Downstream 

Processing 

Formulation 

& Delivery 

Manufacturing 

Clinical & 

Commercial 

Analytical 

& Quality 

Lowest Rates Available Until May 31 u visit www.IBCLifeSciences.com/BPI

download the onsite event guide - IBC Life Sciences

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?